Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 3
1952 4
1956 2
1957 1
1961 1
1962 2
1963 13
1964 7
1965 8
1966 2
1967 6
1968 7
1969 6
1970 5
1971 2
1972 3
1973 3
1974 6
1975 6
1976 4
1977 5
1978 4
1979 3
1980 13
1981 17
1982 13
1983 13
1984 16
1985 19
1986 16
1987 18
1988 15
1989 24
1990 25
1991 20
1992 25
1993 18
1994 19
1995 15
1996 13
1997 24
1998 23
1999 27
2000 31
2001 24
2002 25
2003 27
2004 21
2005 22
2006 22
2007 32
2008 44
2009 46
2010 37
2011 35
2012 49
2013 47
2014 38
2015 27
2016 27
2017 29
2018 23
2019 39
2020 21
2021 23
2022 14
2023 20
2024 18
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,163 results

Results by year

Filters applied: . Clear all
Page 1
European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020.
Husby S, Koletzko S, Korponay-Szabó I, Kurppa K, Mearin ML, Ribes-Koninckx C, Shamir R, Troncone R, Auricchio R, Castillejo G, Christensen R, Dolinsek J, Gillett P, Hróbjartsson A, Koltai T, Maki M, Nielsen SM, Popp A, Størdal K, Werkstetter K, Wessels M. Husby S, et al. Among authors: maki m. J Pediatr Gastroenterol Nutr. 2020 Jan;70(1):141-156. doi: 10.1097/MPG.0000000000002497. J Pediatr Gastroenterol Nutr. 2020. PMID: 31568151
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. Among authors: maki m. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge.
Murray JA, Syage JA, Wu TT, Dickason MA, Ramos AG, Van Dyke C, Horwath I, Lavin PT, Mäki M, Hujoel I, Papadakis KA, Bledsoe AC, Khosla C, Sealey-Voyksner JA; CeliacShield Study Group. Murray JA, et al. Among authors: maki m. Gastroenterology. 2022 Dec;163(6):1510-1521.e6. doi: 10.1053/j.gastro.2022.07.071. Epub 2022 Aug 2. Gastroenterology. 2022. PMID: 35931103 Free PMC article. Clinical Trial.
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease.
Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Mäki M, Ribes-Koninckx C, Ventura A, Zimmer KP; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Husby S, et al. Among authors: maki m. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):136-60. doi: 10.1097/MPG.0b013e31821a23d0. J Pediatr Gastroenterol Nutr. 2012. PMID: 22197856
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.
Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, Sarin J, Huhtala H, Hiltunen P, Zimmermann T, Mohrbacher R, Greinwald R, Lundin KEA, Schuppan D, Mäki M, Viiri K; CEC-3 Investigators. Dotsenko V, et al. Among authors: maki m. Nat Immunol. 2024 Jul;25(7):1218-1230. doi: 10.1038/s41590-024-01867-0. Epub 2024 Jun 24. Nat Immunol. 2024. PMID: 38914866 Free PMC article. Clinical Trial.
Future treatment strategies for celiac disease.
Lindfors K, Lähdeaho ML, Kalliokoski S, Kurppa K, Collin P, Mäki M, Kaukinen K. Lindfors K, et al. Among authors: maki m. Expert Opin Ther Targets. 2012 Jul;16(7):665-75. doi: 10.1517/14728222.2012.688808. Epub 2012 May 24. Expert Opin Ther Targets. 2012. PMID: 22620264 Review.
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Tye-Din JA, Daveson AJM, Goel G, Goldstein KE, Hand HL, Neff KM, Popp A, Taavela J, Maki M, Isola J, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group. Tye-Din JA, et al. Among authors: maki m. Lancet Gastroenterol Hepatol. 2023 May;8(5):446-457. doi: 10.1016/S2468-1253(22)00428-9. Epub 2023 Mar 7. Lancet Gastroenterol Hepatol. 2023. PMID: 36898393 Clinical Trial.
A Review: The Antiviral Activity of Cyclic Peptides.
Chia LY, Kumar PV, Maki MAA, Ravichandran G, Thilagar S. Chia LY, et al. Among authors: maki maa. Int J Pept Res Ther. 2023;29(1):7. doi: 10.1007/s10989-022-10478-y. Epub 2022 Dec 1. Int J Pept Res Ther. 2023. PMID: 36471676 Free PMC article. Review.
1,163 results